Quinazoline derivatives as anticancer drugs: A patent review (2011-present)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 7, 2015, Pages 789-804

  Ravez, Séverine ^a   Castillo Aguilera, Omar ^a,b   Depreux, Patrick ^a,b   Goossens, Laurence ^a,b  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^b Univ Lille   (France)

Author keywords

Cancer; EGFR; Histone deacetylase; Kinase inhibition; Quinazoline

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; BRUTON TYROSINE KINASE INHIBITOR; CN 102311395; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FEBRIFUGINE; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; OXIDOREDUCTASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PRAZOSIN CHLORHYDRATE; PROQUAZONE; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WO 2011025938; WO 2011068187; WO 2011144059; WO 2012055466; WO 2012155339; WO 2013057711; WO 2013178591; WO 2014160177; PROTEIN KINASE INHIBITOR;

DRUG APPROVAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; PROTEIN TARGETING; REVIEW; ANIMAL; DRUG DESIGN; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATENT; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84934931250     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1039512     Document Type: Review

References (79)

1. Griess P. Ueber die Einwirkung des Cyans auf Anthranilsaüre. Berichte 1869;2:415-18
2. Griess P. Ueber die Einwirkung von Cyan auf Amidobenzoësaüre und Anthranilsaüre in Wässeriger Losung. Berichte 1878;11:1985-8
3. Bischler A, Lang M. ZurKenntniss der Phenmiazinderivate. Chem Ber 1895;28:279-93
4. Gabriel S, Colman J. ZurKenntniss des Pyrimidins und methylirter Pyrimidine. Chem Ber 1903;36:3379-85
5. Wang D, Gao F. Quinazoline derivatives: synthesis and bioactivities. Chem Cent J 2013;7:95-110
6. Selvam TP, Kumar PV. Quinazoline marketed drugs-a review. Res Pharm 2011;1:1-21
7. Vijayakumar B, Prasanthi P, Muni Teja K. Quinazoline derivatives & pharmacological activities: a review. IJMCA 2013;3:10-21
8. Coatney GR, Cooper WC, Culwell WB. Studies in human malaria. XXV. Trial of febrifugine, an alkaloid obtained from Dichroafebrifugalour., against the Chesson strain of Plasmodium vivax. J Natl Malar Soc 1950;9:183-6
9. Fishman M, Cruckshank PA. Febrifugine antimalarial agents. 1. Pyridine analogs of febrifugine. J Med Chem 1970;13:155-6
10. Zhu S, Chandrashekar G, Meng L, et al. Febrifugine analogue compounds: synthesis and antimalarial evaluation. Bioorg Med Chem 2012;20:927-32
11. Marzaro G, Guiotto A, Chilin A. Quinazoline derivatives as potential anticancer agents: a patent review (2007-2010). Expert Opin Ther Pat 2012;22:223-52
12. Bilbro J, Mart M, Kyprianou N. Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Res 2013;33:4695-700
13. Van Horn KS, Burda WN, Fleeman R, et al. Antibacterial Activity of a Series of N2, N4 Disubstituted Quinazoline-2, 4-diamines. J Med Chem 2014;57:3075-93
14. Lam T, Hilgers MT, Cunningham ML, et al. Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2, 4-diaminoquinazolines. J Med Chem 2014;57:651-68
15. Singh B, Sharma RA. Anti-inflammatory and antimicrobial properties of pyrroloquinazoline alkaloids from AdhatodavasicaNees. Phytomedicine 2013;20:441-5
16. Hu J, Zhang Y, Dong L, et al. Design, synthesis, and biological evaluation of novel quinazoline derivatives as antiinflammatory agents against lipopolysaccharide-induced acute lung injury in rats. ChemBiol Drug Des 2014; Epub ahead of print
17. Zhu S, Chandrashekar G, Meng L, et al. Febrifugine analogue compounds: synthesis and antimalarial evaluation. Bioorg Med Chem 2012;20:927-32
18. Honkanen E, Pippuri A, Kairisalo P, et al. Synthesis and antihypertensive activity of some new quinazoline derivatives. J Med Chem 1983;26:1433-8
19. Capra M, Nuciforo PG, Confalonieri S, et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res 2006;66:8147-54
20. Holderfield M, Deuker MM, McCormick F. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;14:455-67
21. Wilhelm S, Carter C, Lynch M. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44
22. Daiichi Sankyo Co Ltd Japan. Preparation of quinazoline derivatives as BRAF kinase inhibitors. WO 068187; 2011
23. Peop Rep China. Quinazolinesubstituted diphenyl urea derivatives as Raf kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of leukemia and cancer. CN102311395; 2012
24. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
25. El-Nassan HB. Recent progress in the identification of BRAF inhibitors as anticancer agents. Eur J Med Chem 2014;72:170-205
26. Array BioPharmaInc USA; Genentech Inc. Preparation of N-(3-sulfonylaminophenyl) quinazoline-8-carboxamides as Raf inhibitors. WO 2011025938; 2011
27. Hemmings BA, Restuccia DF. PI3KPKB/Akt pathway. Cold Spring Harb Perspect Biol 2012;4:a011189
28. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13:140-56
29. Welker ME, Kulik G. Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors. Bioorg Med Chem 2013;21:4063-91
30. Merck Patent GmbH. Quinazoline derivatives as PI3 kinase inhibitors and their preparation. WO055466; 2012
31. Exelixis Inc. Preparation of quinazoline compounds as PI3K inhibitors. WO160177; 2014
32. Novartis AG. Preparation of quinazoline derivatives as PI3K modulators. WO057711; 2013
33. Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Oncogene 2015;34:537-45
34. Mortlock AA, Foote KM, Heron NM, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007;50:2213-24
35. Shenzhen Salubris Pharmaceuticals Co. Fused quinazoline derivatives as protein tyrosine kinase inhibitor and aurora kinase inhibitor and their preparation. WO144059; 2011
36. F Hoffmann-La, Roche AG. Aminoquinazoline and pyridopyrimidine derivatives as MAP4K4 inhibitors and their preparation. WO178591; 2013
37. Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist 2003;8:531-8
38. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117-34
39. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-9
40. Denny WA. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. Farmaco 2001;56:51-6
41. Ocanã A, Pandiella A. Targeting HER receptors in cancer. CurrPharm Des 2013;19:808-17
42. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014;79:34-74.
43. Tianjin Inst Pharm Research. 6-substituted quinazoline derivative, preparation method and application thereof. CN102079759; 2011
44. Qilu Pharmaceutical Co Ltd. 4-(Substituted Anilino)Quinazoline Derivatives As Tyrosine Kinase Inhibitors. WO035540; 2011
45. Qilu Pharmaceutical Co Ltd. Polymorphic substances of 4-(substituted anilino)quinazoline derivative xylene sulfonate, and preparation method and application thereof. WO131465; 2013
46. Tetranov International Inc. Bis-Quinazoline derivatives as inhibitors for epidermal growth factor receptor (EGFR) Tyrosine Kinase. US8916572; 2013
47. Carmi C, Lodola A, Rivara S. Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion. Mini Rev Med Chem 2011;11:1019-930
48. Carmi C, Mor M, Petronini PG, et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol 2012;84:1388-99
49. Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 2012;83:407-21
50. Shanghai Allist Pharmaceuticals Inc. Quinazoline derivatives, preparation methods and uses thereof. WO09505; 2011
51. Suzhou Metabomics Inc. Quinolinylcrotyl compound and its application in preparation of antimalignant tumor drugs. CN102838550; 2012
52. Kbp Biosciences Co Ltd. Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof. WO159457; 2012
53. Shanghai Hengrui Pharm Co Ltd. 4-Quinazoline amine derivative and application thereof. WO2013131424; 2014
54. Qilu Pharmaceutical Co Ltd. 4-(Substituted phenylamino)quinazoline compounds, and preparation method and application thereof. CN103965175; 2014
55. KPB biosciences co Ltd. Quinazoline derivatives substituted by aniline, preparation method and use thereof. WO027960; 2012
56. Shanghai Pharmaceuticals Holding Co Ltd. Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof. WO013640; 2013
57. Jiangsu Kanion Pharmaceutical. 4-Phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof. WO155339; 2012
58. Neuwgen Therapeutics Inc. Alkyne substituted quinazoline compound and methods of use. WO122058; 2012
59. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies. Genes Cancer 2011;2:1097-105
60. Tie J, Desai J. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. Crit Rev Oncog 2012;17:51-67
61. Tugues S, Koch S, Gualandi L, et al. Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011;32:88-111
62. Rogosin S, Sandler AB. Beyond bevacizumab: antiangiogenic agents. Clin Lung Cancer 2012;13:326-33
63. Univ Yunnan. Quinazolinearylurea and preparation method and application thereof. CN103102315; 2013
64. Univ Zhejiang. 2-Fluoro-aniline quinazoline tumour positron imaging agents as well as preparation method and application thereof. CN103304493; 2013
65. Univ Beijing Normal. Novel F marked substituted quinazoline compound, and preparation method and tumor PET development application thereof. CN103254140; 2013
66. BoehringerIngelheim Int. Radiolabeled quinazoline derivatives. WO118197; 2014
67. Li S, Wang X, He Y, et al. Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer. Eur J Med Chem 2013;67:293-301
68. Marvania B, Lee PC, Chaniyara R, et al. Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates. Bioorg Med Chem 2011;19:1987-98
69. Univ Beijing Normal. Two nitrogen mustard derivatives, as well as preparation method and application therefore in tumor treatment. CN103450096; 2013
70. Univ Beijing Normal. Crown ether ringshaped quinazoline nitrogen mustard compound, and preparation method and application thereof in tumor treatment. CN103601730; 2014
71. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012;6:579-89
72. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014;124:30-9
73. Jiangsu Hengyi Pharmaceutical Co Ltd. 4-Aminoquinazoline derivatives and uses thereof. WO2012155806; 2014
74. Millennium Pharm Inc. Substituted hydroxamic acids and uses thereof. US0094997; 2012
75. Meitzler JL, Antony S, Wu Y, et al. NADPH oxidases: a perspective on reactive oxygen species production in tumor biology. Antioxid Redox Signal 2014;20:2873-89
76. Univ Emory. Quinazoline derivatives, compositions, and uses related thereto. WO181135; 2013
77. Wang X, Chen M, Zhou J, et al. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review). Int J Oncol 2014;45:18-30
78. Merck Patent Gmbh. Quinazoline derivatives. US238582; 2012
79. Taiho Pharmaceutical Co. Ltd. Novel bicyclic compound or salt thereof. WO093708; 2012